Alphabet's healthcare spinoff, Verily, is doubling the amount of companies in its investment and collaboration hub to about 15 participants.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

GE Ventures is reportedly being considered for a spinoff as part of an ongoing, wide-ranging reorganisation of General Electric.

Based on Lund University research, group B streptococcus vaccine developer Minervax has now raised $11.4m from investors including Novo.

AIG made its second investment in genetic disease drug developer BridgeBio Pharma having also backed a $135m round less than 18 months ago.

The birth control and contraceptive delivery service has increased its funding to $67m altogether in a series B round backed by Alphabet subsidiary GV.

The Legend Capital-backed cancer technology developer has closed a $20.4 round featuring Shougang to increase its total funding to more than $27m.

Novo Holdings has invested more than $22m of its $165m fund across four companies developing drugs meant to combat antimicrobial resistance.

Insurance group Axa has provided $150m for the second early-stage fund to be run by its corporate venturing subsidiary, following its $110m AVP Early Stage I fund in 2015.

Eli Lilly-backed ophthalmic technology developer Avedro has filed for an $86.3m initial public offering having previously raised $220m in debt and equity financing.